

**IN THE UNITED STATES DISTRICT COURT  
FOR THE EASTERN DISTRICT OF PENNSYLVANIA**

**IN RE: GENERIC DIGOXIN AND  
DOXYCYCLINE ANTITRUST  
LITIGATION**

**MDL No. 2724  
No. 16-md-2724**

**THIS DOCUMENT RELATES TO:  
ALL ACTIONS**

**HON. CYNTHIA M. RUFÉ**

**DEFENDANT ACTAVIS HOLDCO U.S., INC.'S  
RULE 7.1 CORPORATE DISCLOSURE STATEMENT**

Pursuant to Federal Rule of Civil Procedure 7.1, Defendant Actavis Holdco U.S., Inc. hereby states that Actavis Holdco U.S., Inc. is a direct subsidiary of Teva Pharmaceuticals USA, Inc., which is an indirect, wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd. (“Teva Ltd.”), which is a publicly-traded company. Teva Ltd. is the only publicly-traded company that owns 10% or more of the stock of Actavis Holdco U.S., Inc.

Dated: March 22, 2017

Respectfully submitted,

**KASOWITZ, BENSON, TORRES  
& FRIEDMAN LLP**

**/s/ Marc E. Kasowitz**

Marc E. Kasowitz  
Hector Torres  
Sheron Korpus  
Seth Davis  
1633 Broadway  
New York, New York 10019  
Tel.: (212) 506-1700  
Fax: (212) 506-1800  
mkasowitz@kasowitz.com  
htorres@kasowitz.com  
skorpus@kasowitz.com  
sdavis@kasowitz.com

*Attorneys for Actavis Holdco U.S.,  
Inc.*

**CERTIFICATE OF SERVICE**

I, Marc E. Kasowitz, hereby certify that a true and correct copy of the foregoing Rule 7.1 Corporate Disclosure Statement was served on all counsel of record via ECF on March 22, 2017. Pursuant to Local Rule 5.1.2(8)(b), I further certify that the foregoing document is available for viewing and downloading on ECF.

Dated: March 22, 2017

**/s/ Marc E. Kasowitz**  
Marc E. Kasowitz